75
Participants
Start Date
December 17, 2019
Primary Completion Date
June 1, 2023
Study Completion Date
June 5, 2026
Apalutamide
Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
Placebo
Matching placebo will be administered orally.
Androgen-deprivation Therapy (ADT)
Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Peking University First Hospital, Beijing
Peking University People s Hospital, Beijing
Beijing Friendship Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Hospital, Beijing
Cancer Hospital, FuDan University, Shanghai
Shanghai Zhongshan Hospital, Shanghai
Huashan Hospital Fudan University, Shanghai
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
The Fifth People's Hospital of Shanghai, Fudan University, Shanghai
Huadong Hospital Affiliated to Fudan University, Shanghai
Nanjing Drum Tower Hospital, Nanjing
Wuxi People s Hospital, Wuxi
First Affiliated Hospital SooChow University, Suzhou
Zhejiang Provincial People's Hospital, Hangzhou
The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Ningbo University, Ningbo
Fujian Medical University Union Hospital, Fuzhou
Chongqing University Cancer Hospital, Chongqing
Hunan Cancer hospital, Changsha
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan
Sun Yat-Sen Memorial Hospital Sun Yat-sen University, Guangzhou
Guangzhou First Municipal People's Hospital, Guangzhou
Sichuan Provincial Peoples Hospital, Chengdu
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
Janssen Research & Development, LLC
INDUSTRY